Analysed ZAI LAB LTD-ADR (ZLAB:NASDAQ) News Sources
How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen’s (AMGN) Risk‑Reward Profile
03-04-2026
yahoo.com
Asian Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
01-04-2026
yahoo.com
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
01-04-2026
yahoo.com
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
27-03-2026
yahoo.com
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
17-03-2026
yahoo.com
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
13-03-2026
yahoo.com
Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
09-03-2026
yahoo.com
What is the current price of ZAI LAB LTD-ADR (ZLAB:NASDAQ)?
The current price of ZAI LAB LTD-ADR (ZLAB:NASDAQ) is $20.68.
ZAI LAB LTD-ADR (ZLAB:NASDAQ) absolute price change since previous trading day?
The absolute price change of ZAI LAB LTD-ADR (ZLAB:NASDAQ) since the previous trading day is $-0.06.
ZAI LAB LTD-ADR (ZLAB:NASDAQ) percentage price change since previous trading day?
The percentage price change of ZAI LAB LTD-ADR (ZLAB:NASDAQ) since the previous trading day is -0.2893%.
What is the most recent average sentiment score for ZAI LAB LTD-ADR (ZLAB:NASDAQ)?
The most recent average sentiment score for ZAI LAB LTD-ADR (ZLAB:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for ZAI LAB LTD-ADR (ZLAB:NASDAQ)?
The most recent sentiment for ZAI LAB LTD-ADR (ZLAB:NASDAQ) is .
SEC-8K** Filing Available For ZAI LAB LTD-ADR (ZLAB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.